Tango Therapeutics, Inc. (TNGX)
Nasdaq · Healthcare · Biotechnology
$23.08−0.69%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.9B
- 52-week range
- $6.69 – $34.39
- 52-week change
- +218.79%
- EPS (trailing)
- −$0.85
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $62.4M (+48.29%)
- Net income
- −$102M
- Operating margin
- −178.4%
- Diluted EPS
- −$0.87
- Free cash flow
- −$140M
From the company’s annual report on SEC EDGAR.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 137 employees · tangotx.com